NCT05248230Phase 2Recruiting

4D-710 in Adult Patients With Cystic Fibrosis

Study sponsor: 4D Molecular Therapeutics

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-06Estimated

Enrollment · participants30Estimated

Source updated2026-07-06Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-11 · 2 fields changed

Enrollment · participant count

Recorded edit

− Previous value

count: 40; type: ESTIMATED

+ Updated value

count: 30; type: ESTIMATED

Primary completion date

Recorded edit

− Previous value

2026-12

+ Updated value

2027-06

Check registry source

Posted 2025-12-11 · 1 field changed

Phase

Recorded edit

− Previous value

PHASE1, PHASE2

+ Updated value

PHASE2

Check registry source

Study details

Conditions studied

Cystic Fibrosis Lung

Treatments or interventions studied

4D-710Biological

Primary outcomes · main study measures

measure: Incidence and severity of adverse events; description: Safety and tolerability of 4D-710 following a single dose via inhalation, as assessed by incidence and severity of treatment emergent adverse events, serious adverse events, and dose limiting toxicities, including clinically significant changes from baseline to scheduled time points in safety parameters.; timeFrame: 60 Months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history